A newly approved drug intended to slow the progression of Alzheimer’s disease offers patients hope, but it will come with a steep price tag: $26,500 a year. The drug, called Leqembi from the drugmakers Eisai and Biogen, was approved by the Food and Drug Administration on Friday for use in people with mild cognitive impairment or early Alzheimer’s disease. [...]
source https://healthyrevue.com/health-wellness/new-alzheimers-drug-leqembi-will-cost-26500-a-year/
No comments:
Post a Comment